Disclaimer: This is an early beta prototype. If you find any error, with data or functionality, please let us know via this page.
Registration date period
Results ordered by trial registration date, descending.
  1. The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Recruiting
    Source name:
    ClinicalTrials.gov

    Our study aims to evaluate the role of ct-DNA and PBMC as biomarkers in the treatment of biliary tract cancer.

    Conditions:
    • Biliary Tract Neoplasms
    Interventions:
    • surgery or biopsy
  2. Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Recruiting
    Source name:
    ClinicalTrials.gov

    A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.

    Conditions:
    • Lung Neoplasms
    • Lung Diseases
    • Bronchial Neoplasms
    • Carcinoma, Non-Small-Cell Lung
    • Carcinoma, Bronchogenic
    Interventions:

    Unknown

  3. Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in Ovarian Cancer (CLIO). Establishing the value of a ctDNA-based HRD assay for predicting olaparib response in women with relapsed ovarian cancer

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    Demonstrate the value of a ctDNA-based assay for homologous recombination deficiency to predict response to olaparib monotherapy. This analysis will also be performed according to platinum-sensitivity...

    Conditions:
    • platinum-sensitive and platinum-resistant relapsed ovarian cancer
    Interventions:
    • OLAPARIB
  4. Clinical Application of CTDNA in Operable Breast Cancer Patients

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Recruiting
    Source name:
    ClinicalTrials.gov

    Our study aims to evaluate the possibility of clinical application of CTDNA detection in samples or peripheral blood of breast cancer patients, so as to act as the new techniques or ...

    Conditions:
    • Breast Cancer
    Interventions:
    • Neoadjuvant chemotherapy before surgery
    • Surgery followed by adjuvant chemotherapy
  5. ctDNA in Patients With Thyroid Nodules

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Recruiting
    Source name:
    ClinicalTrials.gov

    When the DNA inside of human cells undergoes certain alterations (mutations), the cells may develop into a cancer. The cancer cells may shed this DNA into the blood stream. This ...

    Conditions:
    • thyroid cancer
    • Thyroid Adenoma
    • Thyroiditis
    • Thyroid Nodules
    Interventions:

    Unknown

  6. ctDNA for Prediction of Relapse in Gastric Cancer

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Not recruiting
    Source name:
    ClinicalTrials.gov

    Gastric cancer is one of the common malignant tumors in China, with relatively high incident rate and mortality among the population. Surgery is the conventional treatment option for early...

    Conditions:
    • Stomach Neoplasms
    Interventions:
    • ctDNA test
  7. Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Recruiting
    Source name:
    ClinicalTrials.gov

    Lung cancer is the leading cause of cancer death in the U.S. and throughout the world. Lung cancers are broadly divided histologically into small cell lung cancer (SCLC) and non-small cell...

    Conditions:
    • Adenocarcinoma of Lung (Disorder)
    Interventions:
    • Sequencing of ctDNA in plasma
  8. Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Recruiting
    Source name:
    ClinicalTrials.gov

    Genetic rearrangements in the Anaplastic Lymphoma Kinase (ALK) gene result in the creation of a variety of oncogenic fusion proteins that drive malignancy in a subset of non-small cell...

    Conditions:
    • Carcinoma, Non-Small-Cell Lung
    Interventions:

    Unknown